Neurocrine Biosciences's Total Assets for the quarter that ended in Dec. 2023 was R$15,931 Mil.
Warning Sign:
If a company builds assets at 41.1% a year, faster than its revenue growth rate of 28.4% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Neurocrine Biosciences's average Total Assets Growth Rate was 60.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 33.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 41.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 65.20% per year.
During the past 13 years, Neurocrine Biosciences's highest 3-Year average Total Assets Growth Rate was 122.40%. The lowest was -56.20%. And the median was 29.50%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Neurocrine Biosciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (BSP:N1BI34) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Neurocrine Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Neurocrine Biosciences Total Assets Related Terms
Thank you for viewing the detailed overview of Neurocrine Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Neurocrine Biosciences (BSP:N1BI34) Business Description
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:N1BI34 has been successfully added to your 